Calton & Associates’s Antares Pharma, Inc. ATRS Stock Holding History

Calton & Associates’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,500	Closed	-$51K	–	368
2022 Q1	$51K	Buy	12,500 +1,000	+9%	+$3.63K	0.02%	346
2021 Q4	$41K	Sell	11,500 -10,000	-47%	-$35K	0.01%	362
2021 Q3	$78K	Hold	21,500	–	–	0.02%	390
2021 Q2	$94K	Hold	21,500	–	–	0.02%	400
2021 Q1	$88K	Hold	21,500	–	–	0.02%	390
2020 Q4	$86K	Buy	21,500 +1,000	+5%	+$3.23K	0.02%	372
2020 Q3	$55K	Hold	20,500	–	–	0.01%	340
2020 Q2	$56K	Hold	20,500	–	–	0.01%	325
2020 Q1	$48K	Buy	20,500 +3,000	+17%	+$10.2K	0.01%	294
2019 Q4	$82K	Buy	+17,500	New	+$71.6K	0.02%	353
2018 Q1	–	Sell	-3,500	Closed	-$7K	–	1377
2017 Q4	$7K	Buy	+3,500	New	+$7.62K	﹤0.01%	1183

Other funds holding ATRS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Calton & Associates's ATRS Position: Q2 2022 in Review

Calton & Associates sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 12,500 shares — an estimated $51K sold.

Calton & Associates first reported a position in ATRS in Q4 2017 and held it in 11 quarters. The position peaked at $94K in Q2 2021. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.

Calton & Associates reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
Calton & Associates sold 12,500 Antares Pharma, Inc. shares in Q2 2022, an estimated $51K.
Calton & Associates first reported a position in Antares Pharma, Inc. in Q4 2017 and held it in 11 quarters.
Calton & Associates's Antares Pharma, Inc. position peaked at $94K in Q2 2021.
1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.

Based on Calton & Associates's 13F filing for Q2 2022, filed 12 Jul 2022.